MedTrace Logo

Propranolol Dose Escalation in Lymphedema in Patients

NCT02595996 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-10-22

Study results available
· View outcomes & findings →

Summary

This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol treatment.

Conditions

  • Primary Lymphedema

Interventions

DRUG

Propranolol

escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day

Sponsors & Collaborators

Principal Investigators

  • June K. Wu, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-07
Primary Completion
2020-10-08
Completion
2020-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595996 on ClinicalTrials.gov